Werewolf Therapeutics’ (HOWL) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report issued on Monday, RTT News reports. Wedbush currently has a $9.00 target price on the stock.

A number of other equities research analysts have also issued reports on the company. HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research report on Monday. JMP Securities reiterated a market outperform rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a report on Monday.

Werewolf Therapeutics Stock Down 4.2 %

HOWL stock opened at $5.48 on Monday. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. The firm has a 50-day simple moving average of $6.14 and a 200-day simple moving average of $4.73. The stock has a market capitalization of $237.56 million, a P/E ratio of -5.03 and a beta of 0.71.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative return on equity of 36.43% and a negative net margin of 256.33%. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. Equities analysts forecast that Werewolf Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. PFM Health Sciences LP lifted its stake in Werewolf Therapeutics by 35.6% during the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after acquiring an additional 909,895 shares in the last quarter. Denali Advisors LLC acquired a new position in shares of Werewolf Therapeutics in the first quarter valued at approximately $172,000. Lighthouse Investment Partners LLC purchased a new stake in Werewolf Therapeutics during the 4th quarter worth approximately $87,000. Certuity LLC purchased a new position in Werewolf Therapeutics in the 4th quarter valued at approximately $39,000. Finally, Financial Perspectives Inc grew its stake in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after acquiring an additional 3,000 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.